Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group - PubMed (original) (raw)
Clinical Trial
. 2005 Jan 20;23(3):455-60.
doi: 10.1200/JCO.2005.02.129.
M J Moore, E Winquist, T Baetz, M Pollak, K N Chi, S Berry, D S Ernst, L Douglas, M Brundage, B Fisher, A McKenna, L Seymour
Affiliations
- PMID: 15659491
- DOI: 10.1200/JCO.2005.02.129
Clinical Trial
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group
C M Canil et al. J Clin Oncol. 2005.
Abstract
Purpose: Overexpression of the epidermal growth factor receptor has been demonstrated in advanced prostate cancer and is associated with a poor outcome. A multi-institutional, randomized, phase II study was undertaken by the National Cancer Institute of Canada-Clinical Trials Group to evaluate the efficacy and toxicity of two doses of oral gefitinib in patients with minimally symptomatic, hormone-refractory prostate cancer (HRPC).
Patients and methods: Between July and November 2001, 40 patients with HRPC and increasing prostate-specific antigen (PSA) or progression in measurable disease who had not received prior chemotherapy were randomly assigned to 250 mg (n = 19) or 500 mg (n = 21) oral gefitinib daily continuously. The primary end points were PSA response rate and objective measurable response. Functional Assessment of Cancer Therapy Prostate Cancer Subscale (FACT-P) quality-of-life questionnaires were completed at baseline and during treatment.
Results: None of the patients demonstrated a PSA or objective measurable response. Five (14.3%) of 35 assessable patients had stable PSA (one patient at 250 mg and four patients at 500 mg), and five patients (14.3%) had a best response of stable disease (duration, 2.5 to 16.8 months). No significant effect on the rate of increase in PSA was seen. The most common drug-related nonhematologic toxicities observed were grade 1 to 2 diarrhea (250 mg, 65%; 500 mg, 56%), fatigue (250 mg, 29%; 500 mg, 33%), and grade 1 to 2 skin rash (250 mg, 24%; 500 mg, 39%). FACT-P scores decreased during treatment, indicating worsening of symptoms compared with baseline.
Conclusion: Gefitinib did not result in any responses in PSA or objective measurable disease at either dose level. Gefitinib has minimal single-agent activity in HRPC.
Similar articles
- Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nolè F, Verweij F, Matei V, De Cobelli O. Curigliano G, et al. Anticancer Drugs. 2007 Sep;18(8):949-54. doi: 10.1097/CAD.0b013e328136c162. Anticancer Drugs. 2007. PMID: 17667601 Clinical Trial. - An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC. Pezaro C, et al. Am J Clin Oncol. 2009 Aug;32(4):338-41. doi: 10.1097/COC.0b013e31818b946b. Am J Clin Oncol. 2009. PMID: 19363437 Clinical Trial. - A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. Small EJ, et al. BJU Int. 2007 Oct;100(4):765-9. doi: 10.1111/j.1464-410X.2007.07121.x. BJU Int. 2007. PMID: 17822457 Clinical Trial. - The patient with hormone-refractory prostate cancer: determining who, when, and how to treat.
Kent EC, Hussain MH. Kent EC, et al. Urology. 2003 Dec 29;62 Suppl 1:134-40. doi: 10.1016/j.urology.2003.09.005. Urology. 2003. PMID: 14747051 Review. - Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H, Hu L. Aloysius H, et al. Med Res Rev. 2015 May;35(3):554-85. doi: 10.1002/med.21333. Epub 2014 Dec 22. Med Res Rev. 2015. PMID: 25529338 Review.
Cited by
- Signaling Pathways That Control Apoptosis in Prostate Cancer.
Ali A, Kulik G. Ali A, et al. Cancers (Basel). 2021 Feb 24;13(5):937. doi: 10.3390/cancers13050937. Cancers (Basel). 2021. PMID: 33668112 Free PMC article. Review. - Hedgehog signaling in prostate cancer and its therapeutic implication.
Gonnissen A, Isebaert S, Haustermans K. Gonnissen A, et al. Int J Mol Sci. 2013 Jul 4;14(7):13979-4007. doi: 10.3390/ijms140713979. Int J Mol Sci. 2013. PMID: 23880852 Free PMC article. Review. - VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Tsourlakis MC, Khosrawi P, Weigand P, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Krech T, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S. Tsourlakis MC, et al. Int J Mol Sci. 2015 Apr 16;16(4):8591-606. doi: 10.3390/ijms16048591. Int J Mol Sci. 2015. PMID: 25894226 Free PMC article. - Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP. Mahajan K, et al. Prostate. 2010 Sep 1;70(12):1274-85. doi: 10.1002/pros.21163. Prostate. 2010. PMID: 20623637 Free PMC article. - AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells.
Xiao Z, Hammes SR. Xiao Z, et al. iScience. 2021 Oct 14;24(11):103270. doi: 10.1016/j.isci.2021.103270. eCollection 2021 Nov 19. iScience. 2021. PMID: 34761189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous